In this episode of OncoDaily, Dr. Akihito Kawazoe from the National Cancer Center Hospital in Japan presents a Phase 2 trial on regorafenib and nivolumab combined with chemotherapy (K-pox regimen) as a first-line treatment for advanced gastric cancer. The trial showed a 73% objective response rate, a 94% disease control rate, and an 8.3-month median progression-free survival, with a manageable safety profile. Further research is needed to confirm these promising results.

Abstract:- [ Ссылка ]

#GastricCancer #CancerResearch #Oncology #Immunotherapy #Regorafenib #Nivolumab #KPoxRegimen #ClinicalTrials #FirstLineTreatment #CancerTreatment #AdvancedGastricCancer #Phase2Trial #CancerInnovation #GIOncology #JapanCancerResearch #Chemotherapy #ObjectiveResponseRate #DiseaseControlRate #ProgressionFreeSurvival #OncoDaily #Cancer

SUBSCRIBE to get the latest #oncodaily [ Ссылка ]

Visit the OncoDaily Website : [ Ссылка ]
Like OncoDaily on LinkedIn: [ Ссылка ]
Like OncoDaily on X (Twitter): [ Ссылка ]
Follow OncoDaily on Instagram: [ Ссылка ]
Follow OncoDaily on TikTok: [ Ссылка ]
Like OncoDaily on Facebook: [ Ссылка ]

SUBSCRIBE to OncoDaily Newsletter: [ Ссылка ]

About OncoDaily
OncoDaily is a world-leading oncology media platform, which is based in the United States and features the cancer related latest news, insights, and patient stories from around the globe. The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we.”

свернуть